Disease · MONDO_0020528

ACTH-dependent Cushing syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. ACTH-dependent Cushing syndrome. Diseases, record MONDO_0020528. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0020528

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: ACTH-dependent Cushing syndrome; Open Targets
Open Targets ID: MONDO_0020528; Open Targets
Other names: ACTH-dependent CS, Overproduction of ACTH, Pituitary ACTH Hypersecretion, adrenocorticotropic hormone-dependent Cushing syndrome, corticotropin-dependent Cushing syndrome, pituitary-dependent Cushing disease, pituitary-dependent Cushing's disease; Open Targets
Disease Ontology: DOID:3946; Disease Ontology
MeSH: D047748; MeSH
Orphanet: ORPHA:99892; Orphanet
Highest stage of its drugs: Approval, for 2 of its 9 drugs, from DailyMed, EMA Human Drugs and FDA; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PASIREOTIDE	CHEMBL3349607	Protein	Approval	EMA Human Drugs	4	3	3	Drugs and targets
OSILODROSTAT PHOSPHATE	CHEMBL3707393	Small molecule	Approval	DailyMed and FDA	2	0	0	Drugs and targets
MIFEPRISTONE	CHEMBL1276308	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
OSILODROSTAT	CHEMBL3099695	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
FIMEPINOSTAT	CHEMBL3622533	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ROSIGLITAZONE MALEATE	CHEMBL843	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SELICICLIB	CHEMBL14762	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
VORINOSTAT	CHEMBL98	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BEXAROTENE	CHEMBL1023	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets30

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CYP11B1	Cytochrome P450 11B1, mitochondrial	2	Cytochrome P450 11B1 inhibitor	Approval	https://conductscience.org/library/genes/1584	Drugs and targets
HDAC1	Histone deacetylase	2	Histone deacetylase 1 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/3065	Drugs and targets
HDAC2	Histone deacetylase	2	Histone deacetylase 2 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/3066	Drugs and targets
HDAC3	Histone deacetylase	2	Histone deacetylase 3 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/8841	Drugs and targets
HDAC6	Histone deacetylase	2	Histone deacetylase 6 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/10013	Drugs and targets
CDK1	Cyclin-dependent kinase 1	1	Cyclin-dependent kinase 1 inhibitor	Phase 2	https://conductscience.org/library/genes/983	Drugs and targets
CDK2	Cyclin-dependent kinase 2	1	Cyclin-dependent kinase 2 inhibitor	Phase 2	https://conductscience.org/library/genes/1017	Drugs and targets
CDK5	Cyclin-dependent kinase 5	1	Cyclin-dependent kinase 5 inhibitor	Phase 2	https://conductscience.org/library/genes/1020	Drugs and targets
CDK7	Cyclin-dependent kinase 7	1	Cyclin-dependent kinase 7 inhibitor	Phase 2	https://conductscience.org/library/genes/1022	Drugs and targets
CDK9	Cyclin-dependent kinase 9	1	Cyclin-dependent kinase 9 inhibitor	Phase 2	https://conductscience.org/library/genes/1025	Drugs and targets

1 to 10 of 30

See all 30 targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00434148	Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease	Phase 3	162	2013-02-06	Cushing's Disease	PASIREOTIDE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01374906	Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease	Phase 3	150	2018-04-11	Cushing's Disease	PASIREOTIDE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01582061	An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.	Phase 3	104	2018-06-19	Cushing's Disease	PASIREOTIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02697734	Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease	Phase 3	73	2021-10-19	Cushing's Disease	OSILODROSTAT	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00616642	Rosiglitazone in Treating Patients With Pituitary Tumors	Phase 2	1	2013-04-15	Brain and Central Nervous System Tumors	ROSIGLITAZONE MALEATE	Its record names the disease	ClinicalTrials.gov
NCT05971758	Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease	Phase 2	20		Cushing Disease	FIMEPINOSTAT	Open Targets' reading of its record	ClinicalTrials.gov
NCT00845351	Preoperative Bexarotene Treatment for Cushing's Disease	Phase 1/2	6		Cushing's Disease	BEXAROTENE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03774446	Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease	Phase 2	5		Cushing Disease	SELICICLIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01925092	Mifepristone in Children With Refractory Cushing's Disease	Phase 3	0		Cushing's Disease	MIFEPRISTONE	Open Targets' reading of its record	ClinicalTrials.gov
NCT04339751	Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease	Phase 2	0		Cushing's Disease	VORINOSTAT	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Pasireotide 600 ug vs Pasireotide 900 ug: serious adverse events	23 of 82	25 of 80	162	NCT00434148	Trial comparisons
Osilodrostat Group vs Osilodrostat Placebo Group: Time-to-first Control of mUFC - Number (%) of Participants With mUFC <=ULN	45 of 48	8 of 25	73	NCT02697734	Trial comparisons
Osilodrostat Group vs Osilodrostat Placebo Group: Percentage of Randomized Participants With a Complete Response	37 of 48	2 of 25	73	NCT02697734	Trial comparisons

Papers from its trials15

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41052284	DERIVED	1	PubMed
39610378	DERIVED	1	PubMed
35325149	DERIVED	1	PubMed
32385851	DERIVED	1	PubMed
31875276	DERIVED	1	PubMed
31804965	DERIVED	1	PubMed
31465533	DERIVED	1	PubMed
31379734	DERIVED	1	PubMed
29032078	DERIVED	1	PubMed
28289402	DERIVED	1	PubMed

1 to 10 of 15

See all 15 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0020528

GET https://conductscience.org/api/diseases/v1/MONDO_0020528/targets?page=2

API reference For AI assistants